Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post sales of $2.53 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $430,000.00 and the highest is $6.73 million. BioCryst Pharmaceuticals reported sales of $8.76 million during the same quarter last year, which indicates a negative year-over-year growth rate of 71.1%. The firm is expected to issue its next quarterly earnings results before the market opens on Tuesday, November 6th.
On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $22.58 million for the current financial year, with estimates ranging from $17.34 million to $30.16 million. For the next year, analysts expect that the company will post sales of $12.91 million, with estimates ranging from $1.70 million to $19.18 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. The firm had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $3.80 million. BioCryst Pharmaceuticals had a negative net margin of 270.95% and a negative return on equity of 107.85%.
A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 28th. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, September 5th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 13th. They noted that the move was a valuation call. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, October 12th. Finally, Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 15th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $9.89.
In related news, CMO William P. Sheridan sold 62,500 shares of the firm’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $7.03, for a total transaction of $439,375.00. Following the transaction, the chief marketing officer now directly owns 85,713 shares of the company’s stock, valued at $602,562.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas R. Staab II sold 9,850 shares of the firm’s stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total transaction of $71,314.00. Following the transaction, the insider now directly owns 140,633 shares in the company, valued at $1,018,182.92. The disclosure for this sale can be found here. Insiders have sold 75,600 shares of company stock valued at $534,907 over the last quarter. Corporate insiders own 4.50% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Paloma Partners Management Co bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $174,000. Wells Fargo & Company MN lifted its position in shares of BioCryst Pharmaceuticals by 29.3% during the first quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 15,403 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $344,000. State of Wisconsin Investment Board lifted its position in shares of BioCryst Pharmaceuticals by 79.1% during the second quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 44,300 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of BioCryst Pharmaceuticals by 114.2% during the second quarter. Bank of America Corp DE now owns 116,231 shares of the biotechnology company’s stock valued at $666,000 after purchasing an additional 61,960 shares in the last quarter. 79.89% of the stock is currently owned by institutional investors.
Shares of NASDAQ BCRX opened at $7.99 on Friday. BioCryst Pharmaceuticals has a 1 year low of $4.25 and a 1 year high of $8.13. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: Book Value Of Equity Per Share – BVPS Explained
Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.